SLC40A1 and hyperparathyroidism: Bayesian co-localization strongly suggested that PIK3C3 (coloc.abf-PPH4 = 0.93) and SLC40A1 (coloc.abf-PPH4 = 0.58) shared the same variant with hyperparathyroidism , indicating a higher likelihood that these genes may serve as promising drug targets and have an increased probability of obtaining regulatory approval (Fig. 7, Supplemental Table S11).